Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment
ConditionImmune Tolerance
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorStanford University
About this trial
This is a single arm phase 1 non randomized dose finding study for safety, feasibility and efficacy of deceased donor vertebral body (VB) marrow cell infusion and kidney transplantation.
Eligibility criteria
Qualifiers
Patient is ≥ 18 years old, and <65 years of age.
Has End Stage Renal Disease (ESRD) and is a de novo kidney transplant candidate part Stanford standard of care.
Listed with the Organ Procurement and Transplantation Network (OPTN) for deceased donor transplantation.
A serotypic (Human Leucocyte Antigen) HLA match with the donor of a least 1 locus in A, B or DR.
Disqualifiers
Known allergy to rabbit protein.
History of malignancy with the exception of non melanoma skin malignancy.
Pregnant woman or nursing mother.
Body weight >90kg or BMI >35.
Trial design
Treatments tested in this trial
- Combined Deceased Donor Kidney and Hematopoietic Cell Transplants
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov